StrainprintTM Technologies, a Toronto, Canada-based provider of a cannabis data and analytics platform, closed a USD $3M (Cdn.$3.8M) Series A funding.
The round was led by Cesare Fazari, Chairman of Molecular Science Corp and seed investor in Ample Organics and Hydropothecary, with participation from Core Strain Ltd., and a number of Toronto-based capital funds. In conjunction with the funding, Mr. Fazari will also join Strainprint’s Board of Directors.
The company intends to use the proceeds for talent acquisition and expansion of sales and marketing of its Strainprint Analytics web platform across North America and into key international markets like Australia and Germany.
Founded in Toronto in 2016 by CEO Andrew Muroff, Strainprint Technologies is a demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry.
StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. It is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is anonymized and at rest in Canada.
The Strainprint app is free to patients and can be downloaded from both the iOS App and GooglePlay stores while web-based Strainprint Analytics is available by monthly subscription.